Sun Pharma Advanced Research Company (SPARC) has entered into an agreement with Bioprojet SCR (Bioprojet) to exclusively acquire Bioprojet’s rights to the investigational medicinal product SCD-044. SPARC and Bioprojet co-owned all SCD-044 related IP, developed through a research collaboration targeting Sphingosine -1-Phosphate Receptors (S1PR) to treat various autoimmune disorders.
The acquisition includes full assignment of all patents and patent applications owned or controlled by Bioprojet related to SCD-044. Under the terms of the agreement, Bioprojet is eligible to receive milestones and royalties on net sales of SCD-044
SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
